Cytosorbents Share Price (NASDAQ: CTSO)

$0.94

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Cytosorbents Stock chart to analyse performance

Cytosorbents stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$0.94
Today's High:$0.95
$0.94
0.0%
Downside
Day's Volatility :0.83%
Upside
0.83%
52 Weeks Low:$0.71
52 Weeks High:$1.61
$0.94
24.46%
Downside
52 Weeks Volatility :55.89%
Upside
41.61%

Cytosorbents Stock Returns

Period	Cytosorbents Corp	Sector (Health Care)	Index (Russel 2000)
3 Months	10.02%	3.6%	0.0%
6 Months	-8.35%	-7.7%	0.0%
1 Year	-7.45%	-12.6%	0.0%
3 Years	-48.13%	9.5%	-4.7%

Cytosorbents Corp Key Stats

Check Cytosorbents key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$0.94
Open	$0.9451
Today's High	$0.9479
Today's Low	$0.94
Market Capitalization	$59.2M
Today's Volume	$52.6K
52 Week High	$1.61
52 Week Low	$0.7101
Revenue TTM	$36.1M
EBITDA	$-14.8M
Earnings Per Share (EPS)	$-0.18
Profit Margin	-27.32%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-69.67%

Stock Returns calculator for Cytosorbents Stock including INR - Dollar returns

The Cytosorbents stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Cytosorbents investment value today

Current value as on today

₹94,808

Returns

₹5,192

(-5.19%)

Returns from Cytosorbents Stock

₹10,476 (-10.48%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Cytosorbents Stock

-65%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Cytosorbents Stock from India on INDmoney has decreased by -65% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Cytosorbents Corp

Name
Holdings %
Name
Holdings %
Avenir Corporation
8.08%
Skylands Capital, LLC
4.18%
Vanguard Group Inc
3.39%
Neuberger Berman Group LLC
2.68%
CM Management, LLC
2.00%
Sargent Investment Group, LLC
1.32%

Analyst Recommendation on Cytosorbents Stock

Rating

Trend

Buy

77%Buy

22%Hold

0%Sell

Based on 9 Wall street analysts offering stock ratings for Cytosorbents(by analysts ranked 0 to 5 stars)

Cytosorbents Share Price Target

What analysts predicted

Upside of 431.91%

Target:

$5.00

Current:

$0.94

Cytosorbents share price target is $5.00, a slight Upside of 431.91% compared to current price of $0.94 as per analysts' prediction.

Cytosorbents Stock Insights

Price Movement
In the last 7 days, CTSO stock has moved up by 3.4%
Increasing Revenue
Revenue is up for the last 3 quarters, 6.52M → 9.61M (in $), with an average increase of 17.3% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -7.88M → 1.94M (in $), with an average increase of 304.7% per quarter
CTSO vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 29.0% return, outperforming this stock by 39.1%
CTSO vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 163.5% return, outperforming this stock by 216.3%
Price to Sales
ForCTSO every $1 of sales, investors are willing to pay $1.5, whereas for Boston Scientific Corp., the investors are paying $8.4 for every $1 of sales.

Cytosorbents Corp Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$22.8M	↑ 12.41%
Net Income	$-19.3M	↑ 11.94%
Net Profit Margin	-84.63%	↑ 0.35%

	FY20	Y/Y Change
Revenue	$39.5M	↑ 73.3%
Net Income	$-7.8M	↓ 59.32%
Net Profit Margin	-19.86%	↑ 64.77%

	FY21	Y/Y Change
Revenue	$40.1M	↑ 1.66%
Net Income	$-24.6M	↑ 213.37%
Net Profit Margin	-61.23%	↓ 41.37%

	FY22	Y/Y Change
Revenue	$29.4M	↓ 26.8%
Net Income	$-32.8M	↑ 33.61%
Net Profit Margin	-111.76%	↓ 50.53%

	FY23	Y/Y Change
Revenue	$31.1M	↑ 5.88%
Net Income	$-29.2M	↓ 10.87%
Net Profit Margin	-94.09%	↑ 17.67%

	FY24	Y/Y Change
Revenue	$35.6M	↑ 14.51%
Net Income	$-20.7M	↓ 29.16%
Net Profit Margin	-58.21%	↑ 35.88%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$9.0M	↑ 22.34%
Net Income	$-6.4M	↑ 8.96%
Net Profit Margin	-70.73%	↑ 8.68%

	Q2 FY24	Q/Q Change
Revenue	$8.8M	↓ 1.64%
Net Income	$-4.1M	↓ 34.84%
Net Profit Margin	-46.86%	↑ 23.87%

	Q3 FY24	Q/Q Change
Revenue	$8.6M	↓ 2.59%
Net Income	$-2.3M	↓ 43.66%
Net Profit Margin	-27.1%	↑ 19.76%

	Q4 FY24	Q/Q Change
Revenue	$6.5M	↓ 24.27%
Net Income	$-7.9M	↑ 237.79%
Net Profit Margin	-120.86%	↓ 93.76%

	Q1 FY25	Q/Q Change
Revenue	$8.7M	↑ 33.79%
Net Income	$-1.5M	↓ 81.25%
Net Profit Margin	-16.94%	↑ 103.92%

	Q2 FY25	Q/Q Change
Revenue	$9.6M	↑ 10.2%
Net Income	$1.9M	↓ 231.73%
Net Profit Margin	20.25%	↑ 37.19%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$15.4M	↑ 20.68%

	FY20	Y/Y Change
Profit	$28.4M	↑ 84.39%

	FY21	Y/Y Change
Profit	$29.1M	↑ 2.33%

	FY22	Y/Y Change
Profit	$15.4M	↓ 46.99%

	FY23	Y/Y Change
Profit	$22.0M	↑ 42.52%

	FY24	Y/Y Change
Profit	$25.1M	↑ 14.45%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$6.9M	↑ 37.42%

	Q2 FY24	Q/Q Change
Profit	$6.5M	↓ 5.4%

	Q3 FY24	Q/Q Change
Profit	$4.5M	↓ 30.74%

	Q4 FY24	Q/Q Change
Profit	$6.8M	↑ 50.33%

	Q1 FY25	Q/Q Change
Profit	$6.2M	↓ 8.31%

	Q2 FY25	Q/Q Change
Profit	$6.8M	↑ 9.76%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-16.8M	↑ 54.61%
Investing Cash Flow	$-1.5M	↓ 0.01%
Financing Cash Flow	$8.2M	↓ 53.18%

	FY20	Y/Y Change
Operating Cash Flow	$-5.6M	↓ 66.51%
Investing Cash Flow	$-1.7M	↑ 10.27%
Financing Cash Flow	$66.3M	↑ 711.33%

	FY21	Y/Y Change
Operating Cash Flow	$-14.0M	↑ 149.51%
Investing Cash Flow	$-4.3M	↑ 155.41%
Financing Cash Flow	$715.2K	↓ 98.92%

	FY22	Y/Y Change
Operating Cash Flow	$-28.2M	↑ 101.59%
Investing Cash Flow	$-6.5M	↑ 50.79%
Financing Cash Flow	$5.0M	↑ 593.46%

	FY23	Y/Y Change
Operating Cash Flow	$-21.7M	↓ 23.3%
Investing Cash Flow	$-936.2K	↓ 85.5%
Financing Cash Flow	$14.5M	↑ 191.84%

	FY24	Y/Y Change
Operating Cash Flow	$-14.4M	↓ 33.37%
Investing Cash Flow	$-669.4K	↓ 28.5%
Financing Cash Flow	$9.3M	↓ 35.54%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-4.8M	↓ 24.62%
Investing Cash Flow	$-127.0K	↓ 6.55%
Financing Cash Flow	$-571.8K	↓ 104.68%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-4.8M	↓ 0.73%
Investing Cash Flow	$-119.9K	↓ 5.63%
Financing Cash Flow	$9.8M	↓ 1820.06%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-2.5M	↓ 48.67%
Investing Cash Flow	$-298.4K	↑ 148.91%
Financing Cash Flow	$-99.0K	↓ 101.01%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-2.3M	↓ 4.84%
Investing Cash Flow	$-124.2K	↓ 58.37%
Financing Cash Flow	$166.9K	↓ 268.49%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-3.5M	↑ 47.94%
Investing Cash Flow	$-47.2K	↓ 61.96%
Financing Cash Flow	$6.8M	↑ 3994.53%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-1.5M	↓ 56.42%
Investing Cash Flow	$-131.8K	↑ 178.9%
Financing Cash Flow	$-1.1K	↓ 100.02%

Cytosorbents Technicals Summary

Sell

Neutral

Buy

Cytosorbents is currently in a neutral trading position according to technical analysis indicators.

Cytosorbents Corp Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Cytosorbents Corp	11.06%	-8.35%	-7.45%	-48.13%	-88.88%
Medtronic Plc	3.87%	-1.59%	4.32%	4.82%	-13.69%
Edwards Lifesciences Corp.	2.55%	13.95%	18.33%	-9.73%	-5.31%
Boston Scientific Corp.	0.09%	0.6%	30.02%	157.38%	154.4%
Stryker Corporation	3.63%	-0.85%	8.87%	89.43%	97.71%
Abbott Laboratories	5.15%	-5.37%	15.72%	26.56%	24.53%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Cytosorbents Corp	NA	NA	0.0	-0.14	-0.7	-0.2	NA	0.19
Medtronic Plc	25.4	25.4	2.14	5.46	0.1	0.05	0.03	37.36
Edwards Lifesciences Corp.	34.03	34.03	4.85	2.5	0.16	0.08	NA	17.94
Boston Scientific Corp.	62.95	62.95	1.84	2.98	0.12	0.05	NA	15.14
Stryker Corporation	51.54	51.54	2.24	13.49	0.14	0.08	0.01	55.43
Abbott Laboratories	16.64	16.64	4.17	5.14	0.31	0.07	0.02	29.05

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Cytosorbents Corp	Buy	$59.2M	-88.88%	NA	-27.32%
Medtronic Plc	Buy	$118.0B	-13.69%	25.4	13.63%
Edwards Lifesciences Corp.	Buy	$47.8B	-5.31%	34.03	72.96%
Boston Scientific Corp.	Buy	$156.7B	154.4%	62.95	13.55%
Stryker Corporation	Buy	$149.0B	97.71%	51.54	12.25%
Abbott Laboratories	Buy	$230.9B	24.53%	16.64	32.43%

About Cytosorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company's flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, such as severe bleeding, shock, failure to wean from mechanical ventilation, sepsis, and multiple organ failure; DrugSorb-ATR, an antithrombotic removal system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; PuriFi, an advanced hemoperfusion pump for blood purification therapies; and ECOS-300CY, an ex vivo organ perfusion system to preserve or improve the health and quality of harvested solid organs to be transplanted. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Organization	Cytosorbents
Employees	149
CEO	Dr. Phillip P. Chan M.D., Ph.D.
Industry	Health Technology

Key Management of Cytosorbents Corp

Name	Title
Dr. Phillip P. Chan M.D., Ph.D.	CEO & Director
Mr. Vincent J. Capponi M.S.	President & COO
Mr. Peter J. Mariani CPA	Chief Financial Officer
Ms. Kathleen P. Bloch CPA, M.B.A.	Advisor
Dr. Efthymios N. Deliargyris FACC, FESC, FSCAI, M.D.	Chief Medical Officer
Dr. Christian Steiner M.D.	Executive Vice President of Sales & Marketing
Mr. Christopher Cramer M.B.A., M.S.	Senior Vice President of Business Development
Jodi Hoover	Executive
Dr. Robert H. Bartlett M.D.	Co-Chairman of Cardiac Surgery Advisory Board & Consultant

Important FAQs about investing in CTSO Stock from India :

What is Cytosorbents share price today?

Cytosorbents share price today is $0.94 as on August 30, 2025 at 1:29 am IST at the close of the market. Cytosorbents share today touched a day high of $0.95 and a low of $0.94.

What is the 52 week high and 52 week low for Cytosorbents share?

Cytosorbents share touched a 52 week high of $1.61 and a 52 week low of $0.71. Cytosorbents stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $0.94, lower by 41.61% versus the 52 week high.

How to invest in Cytosorbents Stock (CTSO) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Cytosorbents on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Cytosorbents Shares that will get you 1.5957 shares as per Cytosorbents share price of $0.94 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Cytosorbents Stock (CTSO) from India?

Indian investors can start investing in Cytosorbents (CTSO) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Cytosorbents stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Cytosorbents share’s latest price of $0.94 as on August 30, 2025 at 1:29 am IST, you will get 10.6383 shares of Cytosorbents. Learn more about fractional shares .

What are the returns that Cytosorbents has given to Indian investors in the last 5 years?

Cytosorbents stock has given -88.88% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?